Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients

Figure 1 Flowchart of the study design. Dual therapy: Pegylated-interferon-α and ribavirin; HBV: Hepatitis B virus; HCC: Hepatocellular carcinoma; HIV: Human immunodeficiency virus; NVR: Non-virological response; Triple therapy: Telaprevir-based therapy combined with pegylated-interferon-α and ribavirin.

Figure 2 ∆ alpha-fetoprotein decline and %∆ alpha-fetoprotein decline by treatment and virological outcome. ∆AFP decline is defined as the AFP level at 24 wk after end of treatment subtracted from baseline. %∆AFP decline is defined as the percentage of AFP at 24 wk after end of treatment subtracted from baseline. The vertical bars represent the standard errors of the mean. Dual therapy: Pegylated-interferon-α and ribavirin; SVR: Sustained virological response; Triple therapy: Telaprevir-based therapy combined with pegylated-interferon-α and ribavirin; AFP: Alpha-fetoprotein.

Figure 3 ∆ alpha-fetoprotein decline and %∆ alpha-fetoprotein decline by baseline alpha-fetoprotein level (≥ 10 ng/mL and < 10 ng/mL). ∆AFP decline is defined as the AFP level at 24 wk after end of treatment subtracted from baseline. %∆AFP decline is defined as the percentage of AFP at 24 wk after end of treatment subtracted from baseline. The vertical bars represent the standard errors of the mean. Dual therapy: Pegylated-interferon-α and ribavirin; Triple therapy: Telaprevir-based therapy combined with pegylated-interferon-α and ribavirin; AFP: Alpha-fetoprotein.

Figure 4 ∆ alanine aminotransferase decline and %∆alanine aminotransferase decline by baseline alanine aminotransferase level (≥ 40 U/L and < 40 U/L). ∆ALT decline is defined as the ALT level at 24 wk after end of treatment subtracted from baseline. %∆ALT decline is defined as the percentage of ALT at 24 wk after end of treatment subtracted from baseline. The vertical bars represent the standard errors of the mean. Dual therapy: Pegylated-interferon-α and ribavirin; Triple therapy: Telaprevir-based therapy combined with pegylated-interferon-α and ribavirin; ALT: Alanine aminotransferase.